← back to search

Maria I. Carlo

Clinica Mediterranea · US
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, Renal and related cancers, and Cancer Immunotherapy and Biomarkers.
h-index
41
citations
7,782
works
261
NIH funding
primary concept
Medicine
email

Recent publications

NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network 2024cited by 159position: middledoi
Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
Nature Medicine 2023cited by 34position: middledoi
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
European Urology Oncology 2023cited by 15position: middledoi
Epidemiology of Renal Cell Carcinoma: 2022 Update
European Urology 2022cited by 736position: middledoi
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2022cited by 645position: middledoi
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Journal of Clinical Oncology 2022cited by 191position: middledoi
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients
Genome Medicine 2022cited by 43position: middledoi
Disparities in cancer genetics care by race/ethnicity among pan‐cancer patients with pathogenic germline variants
Cancer 2022cited by 41position: middledoi
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
The Oncologist 2022cited by 37position: middledoi
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
CA A Cancer Journal for Clinicians 2022cited by 34position: middledoi
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
European Urology Focus 2022cited by 25position: middledoi
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
Cancer Cell 2021cited by 431position: middledoi
Inherited TP53 Variants and Risk of Prostate Cancer
European Urology 2021cited by 90position: middledoi
Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer
Genetics in Medicine 2021cited by 72position: middledoi
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement
Cancer 2021cited by 44position: middledoi
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
Journal of the National Comprehensive Cancer Network 2020cited by 256position: middledoi
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC
JCO Oncology Practice 2020cited by 53position: middledoi
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
European Urology 2019cited by 115position: firstdoi
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Clinical Genitourinary Cancer 2019cited by 64position: middledoi
Fumarate hydratase<i>FH</i>c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma
Human Mutation 2019cited by 43position: middledoi
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Journal of Clinical Oncology 2018cited by 621position: middledoi
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Journal of Clinical Oncology 2018cited by 549position: middledoi
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
Journal for ImmunoTherapy of Cancer 2018cited by 98position: middledoi
Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting
The Prostate 2018cited by 20position: middledoi
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
JAMA 2017cited by 516position: middledoi
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma
European Urology Focus 2017cited by 39position: middledoi
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
The Oncologist 2016cited by 100position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Ying‐Bei Chen · Johns Hopkins University5 papers (2019–2023)Martin H. Voss · Spanish Oncology Genitourinary Group4 papers (2016–2023)Kenneth Offit · University of Virginia4 papers (2019–2022)Chung‐Han Lee · Exelixis (United States)4 papers (2016–2023)Robert J. Motzer · Texas Oncology4 papers (2016–2023)Zsofia K. Stadler · Cancer Research Center3 papers (2019–2022)Ed Reznik · Motlow State Community College3 papers (2022–2023)Darren R. Feldman · Weill Cornell Medicine3 papers (2016–2023)Ritesh R. Kotecha · Spanish Oncology Genitourinary Group3 papers (2022–2023)Mark E. Robson · University of Edinburgh3 papers (2019–2022)Mark Zucker · Kettering University3 papers (2022–2023)Jonathan Coleman · University Health Network2 papers (2019–2022)A. Ari Hakimi · Manhattan Scientifics (United States)2 papers (2019–2022)Liying Zhang · Beihua University2 papers (2019–2022)Gowtham Jayakumaran · DNA Diagnostic (Denmark)2 papers (2019–2022)Delphine Borchiellini · Observatoire de la Côte d’Azur2 papers (2018–2022)Victor E. Reuter · S.P.E.C.I.E.S.2 papers (2019–2022)Ozge Ceyhan‐Birsoy · Kettering University2 papers (2019–2022)Ahmet Zehir · Natera (United States)2 papers (2019–2022)Erin Salo‐Mullen · Mater Private Hospital2 papers (2021–2022)